רקומבינאט IU 250

البلد: إسرائيل

اللغة: العبرية

المصدر: Ministry of Health

العنصر النشط:

COAGULATION FACTOR VIII RECOMBINANT 250 IU/VIAL

متاح من:

TEVA MEDICAL MARKETING LTD.

ATC رمز:

B02BD02

الشكل الصيدلاني:

POWDER FOR SOLUTION FOR INJECTION

طريقة التعاطي:

I.V

المصنعة من قبل:

BAXTER S.A., BELGIUM

المجموعة العلاجية:

COAGULATION FACTOR VIII

الخصائص العلاجية:

The use of Recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).Recombinate is also indicated in the perioperative management of patients with haemophilia A. Recombinate is appropriate for use in children of all ages including the newborn. (Safety and efficacy studies have been performed in both previously treated and previously untreated children). The product in not suitable for the treatment of von Willebrand's disease.

تاريخ الترخيص:

2010-07-01